newsfilter
← Latest News
GlobeNewswire·

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck